Literature DB >> 14692540

Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy.

Philipp Kiewe1, Sepp Seyfert, Sixten Körper, Kathrin Rieger, Eckhard Thiel, Wolfgang Knauf.   

Abstract

Along with the establishment of more intense chemotherapeutic regimens including fludarabine for the treatment of indolent lymphoproliferative diseases like chronic lymphocytic leukemia (CLL), an increasing amount of cases with progressive multifocal leukoencephalopathy (PML) due to JC virus have been observed. We report a patient with CLL who developed PML parallel to the onset of fludarabine therapy. Spinal fluid was tested positive for JC virus. Despite virostatic treatment with cidofovir, neurologic symptoms were progressive and the disease ultimately fatal. The present case suggests that immunosuppression caused by chronic lymphoproliferative malignancies alone may be a factor in the development of PML. Chemotherapy with fludarabine may act as an additional trigger. The question remains whether serologic screening for JC virus in patients with chronic lymphoproliferative disease undergoing intense chemotherapy might be valuable once sufficient antiviral treatment has been established.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14692540     DOI: 10.1080/1042819031000116625

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

1.  Progressive multifocal leuconcephalopathy and autoimmune haemolytic anemia in chronic lymphocytic leukaemia: more than a fortuitous combination?

Authors:  Carlo Visco; Enrico Marchioni; Fabrizio Pomponi; Pasquale Ferrante; Serena Delbue; Gianpietro Pellizzer; Francesco Rodeghiero
Journal:  Ann Hematol       Date:  2008-08-12       Impact factor: 3.673

Review 2.  The double-edged sword: Neurotoxicity of chemotherapy.

Authors:  Rajiv S Magge; Lisa M DeAngelis
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

Review 3.  Molecular regulation of JC virus tropism: insights into potential therapeutic targets for progressive multifocal leukoencephalopathy.

Authors:  Leslie J Marshall; Eugene O Major
Journal:  J Neuroimmune Pharmacol       Date:  2010-04-17       Impact factor: 4.147

4.  SCIRR39 promotes differentiation of oligodendrocyte precursor cells and regulates expression of myelin-associated inhibitory factors.

Authors:  C F Zhao; Y Liu; H P Que; S G Yang; Z Q Liu; X C Weng; H D Hui; S J Liu
Journal:  J Mol Neurosci       Date:  2013-02-27       Impact factor: 3.444

Review 5.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

6.  Investigation of pre-diagnostic virological markers for progressive multifocal leukoencephalopathy in human immunodeficiency virus-infected patients.

Authors:  Mary K Grabowski; Raphael P Viscidi; Joseph B Margolick; Lisa P Jacobson; Keerti V Shah
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

7.  High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation.

Authors:  J R Long-Boyle; K G Green; C G Brunstein; Q Cao; J Rogosheske; D J Weisdorf; J S Miller; J E Wagner; P B McGlave; P A Jacobson
Journal:  Bone Marrow Transplant       Date:  2010-04-12       Impact factor: 5.483

8.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

9.  Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia.

Authors:  Ann Janssens; Marc Boogaerts; Gregor Verhoef
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.